These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

265 related items for PubMed ID: 15830401

  • 1. An open study of risperidone liquid in the acute phase of schizophrenia.
    Yoshimura R, Nakamura J, Shinkai K, Goto M, Yamada Y, Kaji K, Kakihara S, Ueda N, Kohara K, Ninomiya H, Egami H, Maeda H.
    Hum Psychopharmacol; 2005 Jun; 20(4):243-8. PubMed ID: 15830401
    [Abstract] [Full Text] [Related]

  • 2. Valproic acid improves psychotic agitation without influencing plasma risperidone levels in schizophrenic patients.
    Yoshimura R, Shinkai K, Ueda N, Nakamura J.
    Pharmacopsychiatry; 2007 Jan; 40(1):9-13. PubMed ID: 17327954
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Risperidone in the treatment of psychotic depression.
    Goto M, Yoshimura R, Kakihara S, Shinkai K, Yamada Y, Kaji K, Ueda N, Nakamura J.
    Prog Neuropsychopharmacol Biol Psychiatry; 2006 Jun; 30(4):701-7. PubMed ID: 16580110
    [Abstract] [Full Text] [Related]

  • 5. Oral risperidone with lorazepam versus oral zuclopenthixol with lorazepam in the treatment of acute psychosis in emergency psychiatry: a prospective, comparative, open-label study.
    Hovens JE, Dries PJ, Melman CT, Wapenaar RJ, Loonen AJ.
    J Psychopharmacol; 2005 Jan; 19(1):51-7. PubMed ID: 15671129
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Acute treatment of psychotic agitation: a randomized comparison of oral treatment with risperidone and lorazepam versus intramuscular treatment with haloperidol and lorazepam.
    Currier GW, Chou JC, Feifel D, Bossie CA, Turkoz I, Mahmoud RA, Gharabawi GM.
    J Clin Psychiatry; 2004 Mar; 65(3):386-94. PubMed ID: 15096079
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
    Emsley R, Oosthuizen P, Koen L, Niehaus DJ, Medori R, Rabinowitz J.
    Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
    [Abstract] [Full Text] [Related]

  • 10. Efficacy and safety of long-acting risperidone in elderly patients with schizophrenia and schizoaffective disorder.
    Lasser RA, Bossie CA, Zhu Y, Gharabawi G, Eerdekens M, Davidson M.
    Int J Geriatr Psychiatry; 2004 Sep; 19(9):898-905. PubMed ID: 15352149
    [Abstract] [Full Text] [Related]

  • 11. Prediction of response to risperidone treatment with respect to plasma concencentrations of risperidone, catecholamine metabolites, and polymorphism of cytochrome P450 2D6.
    Kakihara S, Yoshimura R, Shinkai K, Matsumoto C, Goto M, Kaji K, Yamada Y, Ueda N, Ohmori O, Nakamura J.
    Int Clin Psychopharmacol; 2005 Mar; 20(2):71-8. PubMed ID: 15729081
    [Abstract] [Full Text] [Related]

  • 12. Switching to long-acting injectable risperidone is beneficial with regard to clinical outcomes, regardless of previous conventional medication in patients with schizophrenia.
    Marinis TD, Saleem PT, Glue P, Arnoldussen WJ, Teijeiro R, Lex A, Latif MA, Medori R.
    Pharmacopsychiatry; 2007 Nov; 40(6):257-63. PubMed ID: 18030649
    [Abstract] [Full Text] [Related]

  • 13. Treatment with risperidone for 4 weeks increased plasma 3-methoxy-4-hydroxypnenylglycol (MHPG) levels, but did not alter plasma brain-derived neurotrophic factor (BDNF) levels in schizophrenic patients.
    Yoshimura R, Hori H, Sugita A, Ueda N, Kakihara S, Umene W, Nakano Y, Shinkai K, Mitoma M, Ohta M, Shinkai T, Nakamura J.
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Jun 30; 31(5):1072-7. PubMed ID: 17459549
    [Abstract] [Full Text] [Related]

  • 14. Plasma levels of homovanillic acid and the response to risperidone in first episode untreated acute schizophrenia.
    Yoshimura R, Ueda N, Shinkai K, Nakamura J.
    Int Clin Psychopharmacol; 2003 Mar 30; 18(2):107-11. PubMed ID: 12598823
    [Abstract] [Full Text] [Related]

  • 15. Clinical evaluation of risperidone in Asian patients with schizophrenia in Singapore.
    Chong SA, Yap HL, Low BL, Choo CH, Chan AO, Wong KE, Mahendran R, Chee KT.
    Singapore Med J; 1999 Jan 30; 40(1):41-3. PubMed ID: 10361485
    [Abstract] [Full Text] [Related]

  • 16. Randomized clinical comparison of perospirone and risperidone in patients with schizophrenia: Kansai Psychiatric Multicenter Study.
    Okugawa G, Kato M, Wakeno M, Koh J, Morikawa M, Matsumoto N, Shinosaki K, Yoneda H, Kishimoto T, Kinoshita T.
    Psychiatry Clin Neurosci; 2009 Jun 30; 63(3):322-8. PubMed ID: 19566763
    [Abstract] [Full Text] [Related]

  • 17. An open-label, randomized, controlled trial of zotepine and risperidone for acutely ill, hospitalized, schizophrenic patients with symptoms of agitation.
    Chan HY, Lin AS, Chen KP, Cheng JS, Chen YY, Tsai CJ.
    J Clin Psychopharmacol; 2013 Dec 30; 33(6):747-52. PubMed ID: 24100785
    [Abstract] [Full Text] [Related]

  • 18. Long-term treatment with long-acting risperidone in Korean patients with schizophrenia.
    Lee MS, Ko YH, Lee SH, Seo YJ, Kim SH, Joe SH, Han CS, Lee JH, Jung IK.
    Hum Psychopharmacol; 2006 Aug 30; 21(6):399-407. PubMed ID: 16915580
    [Abstract] [Full Text] [Related]

  • 19. Initial treatment of severe acute psychosis with fast orally disintegrating risperidone tablets.
    Normann C, Schmauss M, Bakri N, Gerwe M, Schreiner A.
    Pharmacopsychiatry; 2006 Nov 30; 39(6):209-12. PubMed ID: 17124642
    [Abstract] [Full Text] [Related]

  • 20. [Long-acting injectable risperidone: naturalistic study in three hospitals in Aquitaine].
    Raignoux C, Dusouchet T, Bret P, Queuille E, Biscay ML, Caron J, Bret MC.
    Encephale; 2007 Dec 30; 33(6):973-81. PubMed ID: 18789790
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.